In its proposed rule, FDA states that it does not have the authority to amend the
February 15, 2007, reference date for predicate products with respect to e-cigarettes
or other products. If this is the case, we are very concerned that manufacturers of
newer proposed deemed tobacco products that are ineligible to enter the market
through the substantial equivalence pathway will instead submit premarket tobacco
applications (PMTAs). In its draft guidance for industry on PMTAs, FDA directs
applicants to evaluate the toxicity, abuse liability, and carcinogenicity of their
products using some combination of in vitro, in vivo, or ex vivo studies to
demonstrate that they are appropriate for the protection of the public health. While
we appreciate FDA’s efforts to hold tobacco product manufacturers to this high
standard, it is unconscionable that more animals be made to suffer and die in order to
bring new tobacco products to market. We are also concerned by recent media
reports that FDA is funding inhalation toxicity experiments on mice with e-cigarette
vapor.